Yes, there are different types of GLP-1 agonists, including newer medications called dual and triple agonists that work by targeting more than one hormone
Results showed: Significant increase in skin density and thickness Measurable reduction in fine line depth (up to 35% in some cohorts) Improved skin laxity and elasticity scores Enhanced skin moisture retention These effects are largely attributed to GHK-Cus ability to stimulate fibroblast activity the cells responsible for producing collagen type I and III, elastin, and hyaluronic acid
Research and post-marketing data suggest potential risks, including pancreatitis, gallbladder disease, kidney injury, and progression of diabetic retinopathy
For example, in a UK ED cohort of fallers (patients who have taken a fall) aged 65 years or older, 577 of 1172 received CT scans, but only 28 had an intracranial hemorrhage, and only two received neurosurgical intervention